LG Chem acquires approval of diabetes & dyslipidemia complex for first time in Korea
LG Chem announced ‘Zemiro,’ a complex drug developed for 5 years as a treatment of diabetes and dyslipidemia, was approved to be commercialized in Korea from the Ministry of Food and Drug Safety. It is the first time for a complex drug of diabetes and dyslipidemia to acquire commercialization app...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.